PI-RADS 3-5病变患者系统穿刺中临床显著前列腺癌的检出:大型单中心系列结果
该回顾性研究纳入1506例MRI阳性(PI-RADS≥3)并行系统与MRI靶向穿刺的患者,评估PSAD与MRI表现能否筛选出可安全省略系统穿刺者。结果显示联合穿刺GG≥2癌检出率43%,省略系统穿刺会漏检25%的GG≥2癌(占人群11%),按PI-RADS与PSAD分层无任何亚组漏检率<5%。孤立PI-RADS 3-5病灶者省略对侧系统穿刺仅漏检2.6%的GG≥2癌。
要点
- PSAD与PI-RADS评分无法筛选出可安全完全省略系统穿刺的PI-RADS≥3患者。
- 省略系统穿刺会漏检25%的GG≥2癌,相当于人群11%。
- 孤立PI-RADS 3-5病灶者省略对侧系统穿刺仅漏检2.6%的GG≥2癌。
核心结论
- PSAD和PI-RADS评分未能识别出可安全避免系统穿刺的PI-RADS≥3患者。
- 省略对侧系统穿刺可减少GG1过度诊断,同时保留绝大多数GG≥2癌检出。
研究设计与样本
- 回顾性分析前瞻性维护数据库,纳入MRI阳性(PI-RADS≥3)并行系统与MRI靶向穿刺的患者1506例。
- 主要结局为系统穿刺和/或靶向穿刺检出GG≥2前列腺癌。
- 按PI-RADS评分和PSAD分层,评估省略全部或对侧系统穿刺时漏检GG≥2癌的风险。
主要发现
- 1506例中648例(43%)联合穿刺检出GG≥2癌。
- GG≥2癌检出率随PI-RADS评分升高:PI-RADS 3为19%,4为48%,5为66%。
- GG≥2癌检出率随PSAD升高:<0.1为25%,0.1至<0.15为40%,0.15至<0.2为43%,≥0.2为62%。
- 省略系统穿刺会漏检25%的GG≥2癌(占人群11%)。
- 孤立PI-RADS 3-5病灶者省略对侧系统穿刺仅漏检2.6%的GG≥2癌。
关键数值与推荐
- 按PI-RADS与PSAD分层后,无任何亚组省略系统穿刺的GG≥2癌漏检率<5%。
临床怎么用
- 对PI-RADS≥3患者不应仅凭PSAD和PI-RADS评分完全省略系统穿刺。
- 孤立PI-RADS 3-5病灶者可考虑省略对侧系统穿刺以减少GG1过度诊断。
- 需结合机构具体情况评估该策略的通用性。
局限性
- 回顾性设计。
- 数据通用性可能因设置不同而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the use of PSA density (PSAD) and MRI findings to identify patients that can safely forgo full or partial systematic biopsy while maintaining detection of Grade Group (GG)≥2 prostate cancer. METHODS: From a prospectively maintained database, we performed a retrospective analysis of patients with a positive MRI (PI-RADS ≥3) undergoing systematic and MRI-targeted prostate biopsy. The primary outcome was GG≥2 detection on systematic and/or targeted biopsy. After stratification by PI-RADS score and PSAD, we evaluated the risk of failing to detect GG≥2 cancer if full or contralateral systematic biopsies were omitted. RESULTS: Among 1506 patients who met criteria for inclusion, 648 (43%) had GG≥2 cancer on combined biopsy. Rates of GG≥2 cancer increased with higher PI-RADS score (PI-RADS 3:19%, 4:48%, 5:66%) and PSAD (<0.1: 25%, 0.1 to <0.15: 40%, 0.15 to <0.2: 43%, ≥0.2: 62%). Overall, omission of systematic biopsy would have resulted in missing 25% of GG≥2 cancers (11% of the population). Stratification by PI-RADS and PSAD did not reveal any subgroups in which omitting systematic biopsy would have missed cancer in <5% of patients. In patients with a solitary PI-RADS 3-5 lesion, omitting contralateral systematic biopsies would have missed GG≥2 cancer in only 2.6% of patients. CONCLUSION: In a large academic series, use of PSAD and PI-RADS score did not identify patients with PI-RADS ≥3 mpMRI that could safely avoid systematic biopsy altogether. Acknowledging that the generalizability of these data could vary by setting, our findings suggest that omitting contralateral systematic biopsies could reduce overdiagnosis of GG1 disease while preserving detection of the vast majority of GG≥2 cancers.
引用
- Britton CJ, Assani K, White RE, et al. Detection of Clinically Significant Prostate Cancer on Systematic Biopsy in Patients With a Prostate Imaging Reporting and Data System 3-5 Lesion on Magnetic Resonance Imaging: Results From a Large Institutional Series. Urology. 2026. PMID: 42753979. doi:10.1016/j.urology.2026.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。